There are currently 61 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Metastatic Cancer participants are California, Ohio, Michigan and Illinois.
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
NCT05065736
Recruiting
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Metastatic Cancer, Carcinoma, Adenocarcinoma
Register for Updates
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
NCT06416007
Recruiting
The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Cancer, Metastatic Cancer, Locally Advanced, Locally Advanced Solid Tumor, Locally Advanced Carcinoma
Register for Updates
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575
Recruiting
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Providence Medical Foundation, Santa Rosa, California +97 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Register for Updates
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237
Recruiting
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: University of Miami, Miami, Florida +30 locations
Conditions: Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Register for Updates
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059
Recruiting
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Research Site, Los Angeles, California +25 locations
Conditions: Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Register for Updates
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
NCT06540066
Recruiting
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as a monotherapy or in combination with tislelizumab with or without chemotherapy in participants with selected advanced or metastatic solid tumors. The study will also identify recommended d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California +11 locations
Conditions: Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
Register for Updates
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
NCT06174987
Recruiting
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Miami Cancer Institute, Miami, Florida +27 locations
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626
Recruiting
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin is determined, AU-007 plus aldesleukin will also be administered with aveluma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: START Midwest, Grand Rapids, Michigan +12 locations
Conditions: Advanced Solid Tumor, Metastatic Cancer
Register for Updates
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT05868226
Recruiting
I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama +6 locations
Conditions: HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
Register for Updates
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
NCT05502315
Recruiting
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: University of California San Diego, La Jolla, California +3 locations
Conditions: Castration-resistant Prostate Cancer, Metastatic Cancer
Register for Updates
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
NCT05686226
Recruiting
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Register for Updates
A Study of DS-9606a in Patients With Advanced Solid Tumors
NCT05394675
Recruiting
This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: SCRI at HealthONE, Denver, Colorado +6 locations
Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Germ Cell Tumor
Register for Updates